Vasundhara Rasayans

Vasundhara Rasayans Net Debt / EBITDA

The Net Debt to EBITDA of Vasundhara Rasayans (538634.BO) as of Nov 4, 2026 is -0.38. In the previous year, Net Debt to EBITDA was -1.37 — a change of -72.63% (higher).

Net Debt / EBITDA

-0.38

YoY

-72.63%

Last updated:

Net Debt to EBITDA of Vasundhara Rasayans is 2025 -0.38 . Net Debt to EBITDA of Vasundhara Rasayans was 2024 -1.37 . It decreases by -72.63% higher compared to the previous year.

The Vasundhara Rasayans Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2016
7.04 INR
Jan 1, 2017
2.08 INR
Jan 1, 2020
-1.98 INR
Jan 1, 2021
-3.40 INR
Jan 1, 2022
-4.45 INR
Jan 1, 2023
-0.67 INR
Jan 1, 2024
-1.37 INR
Jan 1, 2025
-0.38 INR
The Vasundhara Rasayans Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
-0.38-72.63%
-1.37+103.50%
-0.67-84.83%
-4.45+30.92%
-3.40+71.17%
-1.98-195.36%
2.08-70.42%
7.04+10.21%
6.39+217.03%
2.01—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vasundhara Rasayans Stock analysis

What does Vasundhara Rasayans do? Vasundhara Rasayans Ltd manufactures and exports active pharmaceutical products for antacid formulations, including Aluminum Hydroxide Gel, Magnesium Hydroxide, Magaldrate, Magnesium Trisilicate, Magnesium Silicate, and Aluminum Phosphate. The company produces these products in paste, powder, and micronized grade powder forms for liquid antacid formulations. It also operates an API intermediate plant with a specialized Friedel Craft reaction facility for organic products. The firm offers Aluminum Hydroxide Gel Low Heavy Lead Content for Lake Color applications and provides Aluminum Hydroxide Amorphous, Aluminum Sulphate, and Poly Aluminum Chloride for water treatment and Aluminum Salts applications. The company's primary customers are pharmaceutical manufacturers requiring antacid therapeutic category Active Pharma Ingredients (API). These manufacturers use Vasundhara Rasayans' products to formulate liquid antacid medications. The firm's API intermediate plant supports the production of organic compounds through its Friedel Craft reaction facility, enhancing its capability to serve the pharmaceutical industry. Vasundhara Rasayans' product range caters to both antacid formulations and specialized applications in water treatment and aluminum salts. Vasundhara Rasayans Ltd generates revenue through the sale of its antacid API products to pharmaceutical companies. The company's manufacturing and export activities focus on delivering high-quality Active Pharma Ingredients for antacid formulations. Its product offerings include specialized variants like Aluminum Hydroxide Gel Low Heavy Lead Content, which targets specific market needs in the pharmaceutical sector. The firm's operations are centered on producing and exporting these pharmaceutical ingredients to meet global demand. Vasundhara Rasayans is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vasundhara Rasayans stock

Net Debt to EBITDA of Vasundhara Rasayans is -0.38 in 2025.

Net Debt to EBITDA of Vasundhara Rasayans changed from -1.37 to -0.38, representing a -72.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Vasundhara Rasayans since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Vasundhara Rasayans with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Vasundhara Rasayans

All Key Metrics — Vasundhara Rasayans